{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T18:21:35Z","timestamp":1779128495745,"version":"3.51.4"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.pcad.2022.05.003","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T02:14:46Z","timestamp":1653012886000},"page":"41-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease"],"prefix":"10.1016","volume":"73","author":[{"given":"Kosmas I.","family":"Paraskevas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Gloviczki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Antignani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Comerota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Dardik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alun H.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Henning","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Faggioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Fernandes e Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustav","family":"Fraedrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Geroulakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Golledge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor S.","family":"Gurevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arkadiusz","family":"Jawien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateja K.","family":"Jezovnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavros K.","family":"Kakkos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Knoflach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Lanza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos D.","family":"Liapis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian M.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Mansilha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew N.","family":"Nicolaides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo","family":"Pini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Poredos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Proczka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Baptiste","family":"Ricco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatjana","family":"Rundek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Saba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Schlachetzki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Silvestrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Stilo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasjit S.","family":"Suri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexei V.","family":"Svetlikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clark J.","family":"Zeebregts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seemant","family":"Chaturvedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank J.","family":"Veith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitri P.","family":"Mikhailidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.pcad.2022.05.003_bb0005","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1161\/01.STR.0000147965.52712.fa","article-title":"Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis","volume":"35","author":"Amarenco","year":"2004","journal-title":"Stroke"},{"issue":"8483","key":"10.1016\/j.pcad.2022.05.003_bb0010","first-page":"1267","article-title":"Cholesterol treatment Trialists\u2019 (CTT) collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.pcad.2022.05.003_bb0015","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1474-4422(09)70058-4","article-title":"Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention","volume":"8","author":"Amarenco","year":"2009","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.pcad.2022.05.003_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejvs.2017.06.021","article-title":"ESVS guidelines committee. Editor\u2019s choice \u2013 Management of Atherosclerotic Carotid and Vertebral Artery Disease: 2017 clinical practice guidelines of the European Society for Vascular Surgery (ESVS)","volume":"55","author":"Naylor","year":"2018","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"47","key":"10.1016\/j.pcad.2022.05.003_bb0025","first-page":"801","article-title":"Diagnosis, treatment and follow-up in extracranial carotid stenosis","volume":"117","author":"Eckstein","year":"2020","journal-title":"Dtsch Arztebl Int"},{"issue":"2","key":"10.1016\/j.pcad.2022.05.003_bb0030","doi-asserted-by":"crossref","first-page":"I","DOI":"10.1177\/23969873211012121","article-title":"European stroke organisation guideline on endarterectomy and stenting for carotid artery stenosis","volume":"6","author":"Bonati","year":"2021","journal-title":"Eur Stroke J"},{"issue":"1S","key":"10.1016\/j.pcad.2022.05.003_bb0035","doi-asserted-by":"crossref","first-page":"4S","DOI":"10.1016\/j.jvs.2021.04.073","article-title":"Society for Vascular Surgery clinical practice guidelines for management of extracranial cerebrovascular disease","volume":"75","author":"AbuRahma","year":"2022","journal-title":"J Vasc Surg"},{"issue":"2","key":"10.1016\/j.pcad.2022.05.003_bb0040","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jvs.2007.03.035","article-title":"Statins: an essential component in the management of carotid artery disease","volume":"46","author":"Paraskevas","year":"2007","journal-title":"J Vasc Surg"},{"issue":"4","key":"10.1016\/j.pcad.2022.05.003_bb0045","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.neurad.2016.12.004","article-title":"The effects of statin therapy on carotid plaque composition and volume: a systematic review and meta-analysis","volume":"44","author":"Brinjikjii","year":"2017","journal-title":"J Neuroradiol"},{"issue":"19","key":"10.1016\/j.pcad.2022.05.003_bb0050","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.21037\/atm.2020.02.176","article-title":"Cholesterol, carotid artery disease and stroke: what the vascular specialist needs to know","volume":"8","author":"Paraskevas","year":"2020","journal-title":"Ann Transl Med"},{"issue":"11","key":"10.1016\/j.pcad.2022.05.003_bb0055","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/eci.12340","article-title":"Carotid atherosclerotic plaque stenosis: the stabilizing role of statins","volume":"44","author":"Artom","year":"2014","journal-title":"Eur J Clin Investig"},{"issue":"5","key":"10.1016\/j.pcad.2022.05.003_bb0060","doi-asserted-by":"crossref","first-page":"10734","DOI":"10.3390\/ijms160510734","article-title":"Ultrasound assessment of carotid plaque echogenicity response to statin therapy: a systematic review and meta-analysis","volume":"16","author":"Ibrahimi","year":"2015","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.pcad.2022.05.003_bb0065","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.atherosclerosis.2011.05.006","article-title":"Three-dimensional ultrasound imaging for the evaluation of carotid atherosclerosis","volume":"219","author":"Makris","year":"2011","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.pcad.2022.05.003_bb0070","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1161\/01.STR.0000042207.16156.B9","article-title":"Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy","volume":"33","author":"Spence","year":"2002","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.pcad.2022.05.003_bb0075","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1532-429X-13-37","article-title":"Carotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance: comparison with ultrasound intima media thickness","volume":"13","author":"Migrino","year":"2011","journal-title":"J Cardiovasc Magn Reson"},{"issue":"5","key":"10.1016\/j.pcad.2022.05.003_bb0080","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ejvs.2015.06.115","article-title":"Long-term mortality in patients with asymptomatic carotid stenosis: implications for statin therapy","volume":"50","author":"Giannopoulos","year":"2015","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"6","key":"10.1016\/j.pcad.2022.05.003_bb0085","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.pcad.2022.05.003_bb0090","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1161\/STROKEAHA.107.493106","article-title":"SPARCL Investigators. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial","volume":"38","author":"Amarenco","year":"2007","journal-title":"Stroke"},{"issue":"12","key":"10.1016\/j.pcad.2022.05.003_bb0095","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1161\/STROKEAHA.108.516450","article-title":"Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial","volume":"39","author":"Sillesen","year":"2008","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.pcad.2022.05.003_bb0100","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ejvs.2006.03.009","article-title":"Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery?","volume":"32","author":"Paraskevas","year":"2006","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"1","key":"10.1016\/j.pcad.2022.05.003_bb0105","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2174\/157016113804547656","article-title":"Perioperative\/periprocedural effects of statin treatment for patients undergoing vascular surgery or endovascular procedures: an update","volume":"11","author":"Paraskevas","year":"2013","journal-title":"Curr Vasc Pharmacol"},{"issue":"5","key":"10.1016\/j.pcad.2022.05.003_bb0110","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/1526602818794030","article-title":"Preoperative use of statins in carotid artery stenting: a systematic review and Meta-analysis","volume":"25","author":"Texakalidis","year":"2018","journal-title":"J Endovasc Ther"},{"issue":"4","key":"10.1016\/j.pcad.2022.05.003_bb0115","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1053\/j.semvascsurg.2007.10.008","article-title":"The effect of statin medications on perioperative and long-term outcomes following carotid endarterectomy or stenting","volume":"20","author":"Perler","year":"2007","journal-title":"Semin Vasc Surg"},{"issue":"16","key":"10.1016\/j.pcad.2022.05.003_bb0120","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009745","article-title":"Association between statin use and cardiovascular events after carotid artery revascularization","volume":"7","author":"Hussain","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.pcad.2022.05.003_bb0125","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.bja.2020.01.010","article-title":"The case for statin use to reduce perioperative adverse cardiovascular and cerebrovascular events","volume":"124","author":"Ratcliffe","year":"2020","journal-title":"Br J Anaesth"},{"issue":"6","key":"10.1016\/j.pcad.2022.05.003_bb0130","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/MOL.0000000000000638","article-title":"Lipid management in people with peripheral artery disease","volume":"30","author":"Golledge","year":"2019","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.pcad.2022.05.003_bb0135","article-title":"Effects of statins in primary and secondary prevention for venous thromboembolism events: a meta-analysis","volume":"142","author":"Zhu","year":"2021","journal-title":"Vasc Pharmacol"},{"key":"10.1016\/j.pcad.2022.05.003_bb0140","article-title":"Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials","author":"Joseph","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10.1016\/j.pcad.2022.05.003_bb0145","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/nrneph.2013.249","article-title":"Acute kidney injury: short-term statin therapy for prevention of contrast-induced AKI","volume":"10","author":"Mikhailidis","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.pcad.2022.05.003_bb0150","article-title":"Contrast-induced nephropathy in non-cardiac vascular procedures, a narrative review: part I","author":"Raffort","year":"2021","journal-title":"Curr Vasc Pharmacol"},{"issue":"6","key":"10.1016\/j.pcad.2022.05.003_bb0155","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1185\/030079903125002225","article-title":"Early vascular benefits of statin therapy","volume":"19","author":"Tsiara","year":"2003","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.1016\/j.pcad.2022.05.003_bb0160","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1517\/14740338.2015.1039980","article-title":"Statin intolerance - an attempt at a unified definition. Position paper from an international lipid expert panel","volume":"14","author":"Banach","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"10.1016\/j.pcad.2022.05.003_bb0165","first-page":"225","article-title":"Statin intolerance: some practical hints","volume":"36","author":"Banach","year":"2018","journal-title":"Cardiol Clin"},{"issue":"6","key":"10.1016\/j.pcad.2022.05.003_bb0170","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1517\/17425255.2015.1027685","article-title":"Strategies to overcome statin intolerance","volume":"11","author":"Agouridis","year":"2015","journal-title":"Expert Opin Drub Metab Toxicol"},{"issue":"9","key":"10.1016\/j.pcad.2022.05.003_bb0175","first-page":"605","article-title":"Statins and liver injury","volume":"9","author":"Thapar","year":"2013","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"4","key":"10.1016\/j.pcad.2022.05.003_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101816","article-title":"Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis","volume":"46","author":"Fatima","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"10","key":"10.1016\/j.pcad.2022.05.003_bb0185","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2174\/1389450122666210120125945","article-title":"Role of statins in new-onset diabetes mellitus: the underlying cause, mechanisms involved, and strategies to combat","volume":"22","author":"Keni","year":"2021","journal-title":"Curr Drug Targets"},{"issue":"6","key":"10.1016\/j.pcad.2022.05.003_bb0190","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/CRD.0000000000000348","article-title":"Statins and higher diabetes mellitus risk: incidence, proposed mechanisms, and clinical implications","volume":"29","author":"Guber","year":"2021","journal-title":"Cardiol Rev"},{"issue":"12","key":"10.1016\/j.pcad.2022.05.003_bb0195","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1001\/jamainternmed.2021.5714","article-title":"Association of Statin Therapy Initiation with Diabetes Progression: a retrospective matched-cohort study","volume":"181","author":"Mansi","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"11","key":"10.1016\/j.pcad.2022.05.003_bb0200","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1185\/03007990802469102","article-title":"Statin discontinuation: an underestimated risk?","volume":"24","author":"Tziomalos","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"10.1016\/j.pcad.2022.05.003_bb0205","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/1074248419838499","article-title":"Statins\u2019 withdrawal induces atherosclerotic plaque destabilization in animal model-a \u201crebound\u201d stimulation of inflammation","volume":"24","author":"Stasinopoulou","year":"2019","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"S1","key":"10.1016\/j.pcad.2022.05.003_bb0210","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.3909\/ricm19S1S0002","article-title":"PCSK9 inhibitors: mechanism of action, efficacy, and safety","volume":"19","author":"Roth","year":"2018","journal-title":"Rev Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.pcad.2022.05.003_bb0215","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00701-019-03825-4","article-title":"Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab","volume":"161","author":"Ogata","year":"2019","journal-title":"Acta Neurochir"},{"issue":"6","key":"10.1016\/j.pcad.2022.05.003_bb0220","first-page":"E835","article-title":"Morphological stabilization and regression of carotid plaque following therapy with evolocumab in a high-risk patient","volume":"97","author":"Aranzulla","year":"2021","journal-title":"Catheter Cardiovasc Interv"},{"issue":"12","key":"10.1016\/j.pcad.2022.05.003_bb0225","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1016\/j.jcmg.2019.06.022","article-title":"PCSK9 antibody Alirocumab attenuates Arterial Wall inflammation without changes in circulating inflammatory markers","volume":"12","author":"Hoogeveen","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"10.1016\/j.pcad.2022.05.003_bb0230","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.numecd.2020.02.018","article-title":"Changes in carotid stiffness in patients with familiar hypercholesterolemia treated with Evolocumab\u00ae: a prospective cohort study","volume":"30","author":"Di Minno","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"12","key":"10.1016\/j.pcad.2022.05.003_bb0235","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/j.numecd.2020.09.016","article-title":"Evolocumab improves intima media thickness regression in HeFH subjects on lipoprotein apheresis","volume":"30","author":"Sbrana","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"18","key":"10.1016\/j.pcad.2022.05.003_bb0240","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.pcad.2022.05.003_bb0245","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1161\/STROKEAHA.119.027759","article-title":"FOURIER investigators. Stroke prevention with the PCSK9 (Proprotein convertase Subtilisin-Kexin type 9) inhibitor Evolocumab added to statin in high-risk patients with stable atherosclerosis","volume":"51","author":"Giugliano","year":"2020","journal-title":"Stroke"},{"issue":"25","key":"10.1016\/j.pcad.2022.05.003_bb0250","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/CIRCULATIONAHA.119.043826","article-title":"ODYSSEY OUTCOMES investigators. Effect of Alirocumab on stroke in ODYSSEY OUTCOMES","volume":"140","author":"Jukema","year":"2019","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.pcad.2022.05.003_bb0255","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s10554-020-02115-w","article-title":"Serial magnetic resonance imaging detects a rapid reduction in plaque lipid content under PCSK9 inhibition with alirocumab","volume":"37","author":"Sun","year":"2021","journal-title":"Int J Card Imaging"},{"key":"10.1016\/j.pcad.2022.05.003_bb0260","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.atherosclerosis.2021.05.008","article-title":"Regression in carotid plaque lipid content and neovasculature with PCSK9 inhibition: a time course study","volume":"327","author":"Lepor","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pcad.2022.05.003_bb0265","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.atherosclerosis.2021.04.008","article-title":"Meta-analysis of randomized clinical trials comparing PCSK9 monoclonal antibody versus ezetimibe\/placebo in patients at high cardiovascular risk","volume":"326","author":"Ma","year":"2021","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.pcad.2022.05.003_bb0270","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.10.009","article-title":"Impact of additional lipid-lowering therapy on new ischemic lesions of diffusion-weighted imaging in carotid artery stenting","volume":"27","author":"Mizobe","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.pcad.2022.05.003_bb0275","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1016\/j.wneu.2019.10.095","article-title":"Effect of preoperative Administration of Proprotein Convertase Subtilisin\/Kexin type 9 inhibitor on carotid artery stenting","volume":"135","author":"Shingai","year":"2020","journal-title":"World Neurosurg"},{"issue":"1","key":"10.1016\/j.pcad.2022.05.003_bb0280","first-page":"E115","article-title":"CARotid plaqUe StabilizatiOn and regression with evolocumab: rationale and design of the CARUSO study","volume":"98","author":"Aranzulla","year":"2021","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2022.05.003_bb0285","series-title":"StatPearls [Internet]","article-title":"PCSK9 Inhibitors. 2021 Jul 18","author":"Pokhrel","year":"2021"},{"issue":"4","key":"10.1016\/j.pcad.2022.05.003_bb0290","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.clinthera.2021.02.002","article-title":"Effectiveness, safety, and adherence to treatment of Proprotein convertase Subtilisin\/Kexin type 9 inhibitors in real practice","volume":"43","author":"Gayoso-Rey","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.pcad.2022.05.003_bb0295","first-page":"191","article-title":"Safety and tolerability of PCSK9 inhibitors: current insights","volume":"12","author":"Kosmas","year":"2020","journal-title":"Clin Pharm"},{"issue":"8","key":"10.1016\/j.pcad.2022.05.003_bb0300","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.2337\/dc20-1533","article-title":"Fenofibrate use is associated with lower mortality and fewer cardiovascular events in patients with diabetes: results of 10,114 patients from the Korean National Health Insurance Service cohort","volume":"44","author":"Jo","year":"2021","journal-title":"Diabetes Care"},{"issue":"15","key":"10.1016\/j.pcad.2022.05.003_bb0305","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.pcad.2022.05.003_bb0310","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2174\/157016111796197198","article-title":"Carotid intima-media thickness and ezetimibe: the end of a misunderstanding?","volume":"9","author":"Paraskevas","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"issue":"10","key":"10.1016\/j.pcad.2022.05.003_bb0315","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1007\/s12325-021-01892-7","article-title":"Adherence to lipid-lowering treatment by single-pill combination of statin and ezetimibe","volume":"38","author":"Rea","year":"2021","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.pcad.2022.05.003_bb0320","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jacc.2009.07.062","article-title":"Cholesterol-lowering interventions and stroke: insight from a meta-analysis of randomized controlled trials","volume":"55","author":"De Caterina","year":"2010","journal-title":"J Am Coll Cardiol"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062022000469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062022000469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:20:21Z","timestamp":1758500421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062022000469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":64,"alternative-id":["S0033062022000469"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2022.05.003","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2022.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}